PMID- 25972062
OWN - NLM
STAT- MEDLINE
DCOM- 20160511
LR  - 20220408
IS  - 1941-6636 (Electronic)
IS  - 1941-6628 (Print)
VI  - 46
IP  - 3
DP  - 2015 Sep
TI  - A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World 
      Impact on Survival, Quality of Life and Costs.
PG  - 201-11
LID - 10.1007/s12029-015-9724-1 [doi]
AB  - PURPOSE: The purpose of this study was to assess the overall burden of pancreatic 
      cancer in Europe, with a focus on survival time in a real-world setting, and the 
      overall healthy life lost to the disease. METHODS: Real-world data were retrieved 
      from peer-reviewed, observational studies identified by an electronic search. We 
      performed two de novo analyses: a proportional shortfall analysis to quantify the 
      proportion of healthy life lost to pancreatic cancer and an estimation of the 
      aggregate life-years lost annually in Europe. RESULTS: Ninety-one studies were 
      included. The median, age-standardised incidence of pancreatic cancer per 100,000 
      was 7.6 in men and 4.9 in women. Overall median survival from diagnosis was 4.6 
      months; median survival was 2.8-5.7 months in patients with metastatic disease. 
      The proportional shortfall analysis showed that pancreatic cancer results in a 98 
      % loss of healthy life, with a life expectancy at diagnosis of 4.6 months 
      compared to 15.1 years for an age-matched healthy population. Annually, 
      610,000-915,000 quality-adjusted life-years (QALYs) are lost to pancreatic cancer 
      in Europe. Patients had significantly lower scores on validated health-related 
      quality of life instruments versus population norms. CONCLUSIONS: To the best of 
      our knowledge, this is the first study to systematically review real-world 
      overall survival and patient outcomes of pancreatic cancer patients in Europe 
      outside the context of clinical trials. Our findings confirm the poor prognosis 
      and short survival reported by national studies. Pancreatic cancer is a 
      substantial burden in Europe, with nearly a million aggregate life-years lost 
      annually and almost complete loss of healthy life in affected individuals.
FAU - Carrato, A
AU  - Carrato A
AD  - Medical Oncology Department, Ramon y Cajal University Hospital, Ctra. Colmenar 
      Viejo Km. 9,100, Madrid, Spain.
FAU - Falcone, A
AU  - Falcone A
FAU - Ducreux, M
AU  - Ducreux M
FAU - Valle, J W
AU  - Valle JW
FAU - Parnaby, A
AU  - Parnaby A
FAU - Djazouli, K
AU  - Djazouli K
FAU - Alnwick-Allu, K
AU  - Alnwick-Allu K
FAU - Hutchings, A
AU  - Hutchings A
FAU - Palaska, C
AU  - Palaska C
FAU - Parthenaki, I
AU  - Parthenaki I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - J Gastrointest Cancer
JT  - Journal of gastrointestinal cancer
JID - 101479627
SB  - IM
MH  - Aged
MH  - Europe
MH  - Female
MH  - Humans
MH  - Male
MH  - Pancreatic Neoplasms/*diagnosis/economics/mortality
MH  - Quality of Life
MH  - Survival Analysis
PMC - PMC4519613
EDAT- 2015/05/15 06:00
MHDA- 2016/05/12 06:00
PMCR- 2015/05/14
CRDT- 2015/05/15 06:00
PHST- 2015/05/15 06:00 [entrez]
PHST- 2015/05/15 06:00 [pubmed]
PHST- 2016/05/12 06:00 [medline]
PHST- 2015/05/14 00:00 [pmc-release]
AID - 9724 [pii]
AID - 10.1007/s12029-015-9724-1 [doi]
PST - ppublish
SO  - J Gastrointest Cancer. 2015 Sep;46(3):201-11. doi: 10.1007/s12029-015-9724-1.